卡瑞利珠单抗联合化疗治疗晚期非小细胞肺癌的真实世界疗效与安全性分析
Real-World Efficacy and Safety Analysis of Camrelizumab Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer
DOI: 10.12677/acm.2026.1641513, PDF,    科研立项经费支持
作者: 任芳芳, 刘 洋, 袁婷婷, 王西勇*：安徽医科大学附属宿州医院肿瘤科，安徽 宿州
关键词: 卡瑞利珠单抗；免疫治疗；肿瘤标志物；不良反应；生存时间；Camrelizumab； Immunotherapy； Tumor Markers； Adverse Reactions； Survival Time
摘要: 目的：评估卡瑞利珠单抗联合化疗在晚期非小细胞肺癌(NSCLC)患者中的真实世界疗效和安全性。方法：回顾性纳入2020年1月~2023年12月安徽医科大学附属宿州医院收治的120例晚期NSCLC患者，按治疗方案分为联合组(卡瑞利珠单抗 + 化疗，n = 64)和对照组(单纯化疗，n = 56)。比较两组治疗4周期后的近期疗效、血清肿瘤标志物、不良反应及24个月生存结局。结果：联合组客观缓解率(ORR)与疾病控制率(DCR)高于对照组，差异有统计学意义(均P < 0.01)。联合组肿瘤标志物水平低于对照组，差异有统计学意义(均P < 0.01)。联合组反应性皮肤毛细血管内皮增生症(RCCEP)及甲状腺功能减退发生率高于对照组，差异有统计学意义(均P < 0.01)；其余不良反应组间无统计学差异。Log-rank检验显示，联合组中位无进展生存期(PFS)与总生存期(OS)高于对照组，差异有统计学意义(均P < 0.05)。24个月OS率及PFS率高于对照组，差异有统计学意义(均P < 0.05)。结论：真实世界研究表明，卡瑞利珠单抗在晚期非小细胞肺癌治疗中具有显著疗效，且联合治疗的效果更佳。
Abstract: Objective: To evaluate the real-world efficacy and safety of camrelizumab combined with chemotherapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC). Methods: A retrospective analysis was conducted on 120 advanced NSCLC patients treated at Suzhou Hospital Affiliated to Anhui Medical University between January 2020 and December 2023. Participants were divided into two groups: the combination group (camrelizumab + chemotherapy, n = 64) and the control group (chemotherapy alone, n = 56). Short-term efficacy, serum tumor markers, Adverse Events (AEs), and 24-month survival outcomes were compared after 4 treatment cycles. Results: The combination group demonstrated significantly higher Objective Response Rate (ORR) and Disease Control Rate (DCR) versus the control group (all P < 0.01). Serum tumor marker levels were significantly lower in the combination group (all P < 0.01). Incidence rates of Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) and hypothyroidism were significantly higher in the combination group (all P < 0.01), while other AEs showed no statistical differences. Log-rank tests revealed significantly prolonged median Progression-Free Survival (PFS) and Overall Survival (OS) in the combination group (all P < 0.05). The 24-month OS and PFS rates were also significantly higher in the combination group (all P < 0.05).
文章引用：任芳芳, 刘洋, 袁婷婷, 王西勇. 卡瑞利珠单抗联合化疗治疗晚期非小细胞肺癌的真实世界疗效与安全性分析 [J]. 临床医学进展, 2026, 16(4): 2616-2623. https://doi.org/10.12677/acm.2026.1641513

参考文献

[1] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. [Google Scholar] [CrossRef] [PubMed]
[2] Siegel, R.L., Kratzer, T.B., Giaquinto, A.N., Sung, H. and Jemal, A. (2025) Cancer Statistics, 2025. CA: A Cancer Journal for Clinicians, 75, 10-45. [Google Scholar] [CrossRef] [PubMed]
[3] Tsao, M.S., Rosenthal, A., Nicholson, A.G., Detterbeck, F., Eberhardt, W.E.E., Lievens, Y., et al. (2025) The International Association for the Study of Lung Cancer Staging Project: The Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 20, 856-870. [Google Scholar] [CrossRef] [PubMed]
[4] Wang, Q., Su, C. and Zhou, C. (2023) Recent Advances in Immunotherapy for Lung Cancer. Cancer Innovation, 2, 18-24. [Google Scholar] [CrossRef] [PubMed]
[5] Hendriks, L.E.L., Remon, J., Faivre-Finn, C., Garassino, M.C., Heymach, J.V., Kerr, K.M., et al. (2024) Non-Small-Cell Lung Cancer. Nature Reviews Disease Primers, 10, Article No. 71. [Google Scholar] [CrossRef] [PubMed]
[6] Zhou, C., Chen, G., Huang, Y., Zhou, J., Lin, L., Feng, J., et al. (2021) Camrelizumab plus Carboplatin and Pemetrexed versus Chemotherapy Alone in Chemotherapy-Naive Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer (CameL): A Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet Respiratory Medicine, 9, 305-314. [Google Scholar] [CrossRef] [PubMed]
[7] Ren, S., Chen, J., Xu, X., Jiang, T., Cheng, Y., Chen, G., et al. (2022) Camrelizumab plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. Journal of Thoracic Oncology, 17, 544-557. [Google Scholar] [CrossRef] [PubMed]
[8] Nelles, C., Gräf, M., Bernard, P., Persigehl, T., Große Hokamp, N., Zopfs, D., et al. (2024) Real-World Response Assessment of Immune Checkpoint Inhibition: Comparing iRECIST and RECIST 1.1 in Melanoma and Non-Small Cell Lung Cancer Patients. European Radiology, 35, 2084-2093. [Google Scholar] [CrossRef] [PubMed]
[9] Zhou, C., Chen, G., Huang, Y., et al. (2024) Camrelizumab plus Carboplatin and Pemetrexed as First-Line Therapy for Advanced Non-Squamous Non-Small-Cell Lung Cancer: 5-Year Outcomes of the CameL Randomized Phase 3 Study. The Journal for ImmunoTherapy of Cancer, 12, e009240.
[10] Xu, C., Chen, Q., Zhou, C., Wu, L., Li, W., Zhang, H., et al. (2023) Effectiveness and Safety of Camrelizumab in Inoperable or Advanced Non-Small Cell Lung Cancer Patients: A Multicenter Real-World Retrospective Observational Study (CTONG2004-ADV). Translational Lung Cancer Research, 12, 127-140. [Google Scholar] [CrossRef] [PubMed]
[11] Juarez-Garcia, A., Sharma, R., Hunger, M., Kayaniyil, S., Penrod, J.R. and Chouaïd, C. (2022) Real-World Effectiveness of Immunotherapies in Pre-Treated, Advanced Non-Small Cell Lung Cancer Patients: A Systematic Literature Review. Lung Cancer, 166, 205-220. [Google Scholar] [CrossRef] [PubMed]
[12] Strum, S., Vincent, M., Gipson, M., McArthur, E. and Breadner, D. (2024) Assessment of Serum Tumor Markers CEA, CA-125, and CA19-9 as Adjuncts in Non-Small Cell Lung Cancer Management. Oncotarget, 15, 381-388. [Google Scholar] [CrossRef] [PubMed]
[13] 徐菊娣, 黄骞, 杨志勇, 等. 卡瑞利珠单抗辅助化疗对中晚期NSCLC患者的近期疗效及对细胞免疫、血清肿瘤标志物的影响[J]. 现代肿瘤医学, 2023, 31(6): 1047-1051.
[14] Xu, M., Meng, X., Lu, Y. and Wang, F. (2022) Efficacy and Safety of Camrelizumab in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment for Patients with Her2-Positive Advanced Gastric Cancer. Journal of Gastrointestinal Oncology, 13, 548-558. [Google Scholar] [CrossRef] [PubMed]
[15] Zhao, D., Bi, M., Cheng, X., Wang, S., Cheng, H., Xia, X., et al. (2025) Camrelizumab-Based Therapies for the Treatment of Advanced Lung Cancer: A Prospective, Open-Label, Multicenter, Observational, Real-World Study. Frontiers in Immunology, 16, Article ID: 1494708. [Google Scholar] [CrossRef] [PubMed]
[16] Wang, R., Shi, M., Ji, M., Han, Z., Chen, L., Liu, Y., et al. (2023) Real World Experience with Camrelizumab in Patients with Advanced Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (NOAH-LC-101). Translational Lung Cancer Research, 12, 786-796. [Google Scholar] [CrossRef] [PubMed]
[17] Lv, J., Zhang, W., Deng, R., Chen, Y., Liu, M., Zhang, Z., et al. (2022) Efficacy, Safety and Prognostic Factors of Camrelizumab plus Carboplatin and Pemetrexed Chemotherapy in Advanced Lung Adenocarcinoma Patients. Journal of Clinical Pharmacy and Therapeutics, 47, 1257-1263. [Google Scholar] [CrossRef] [PubMed]

为你推荐